

Statement of Discontinuation

Statement of Discontinuation of the study
Name of Sponsor: Ghent University Hospital
Study No: 2019-002597-32
Product: Tilmanocept
Title: Comparison of dynamics and tracer distribution of Tilmanocept and Nanoscintcoll using a combined subareolar and peritumoral injection technique for scintigraphic sentinel lymph node detection in early stage breast cancer
Phase: IV
Study Period: 01-Jul-2020 until 05-Jan-2021
Centres: Ghent University Hospital
Number of Subjects: 0
Publications: NA
Statement on discontinuation of the study: Study has been terminated as no patients have been screened